Emerald Kalama Chemical

Photo

Lanxess to Acquire Emerald Kalama Chemical

Germany’s Lanxess has signed a binding agreement to acquire 100% of Emerald Kalama Chemical from affiliates of private equity firm American Securities. The US specialty chemicals producer focused mainly on consumer markets last reported sales of $425 million and EBITDA pre-exceptionals of $90 million. Closing is expected in the second half of 2021, subject to regulatory approval.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.